Antiphospholipid Antibodies and Reproduction

American Journal of Reproductive Immunology

Volumn 21, Issue 3-4, 1989, Pages 123-131

  TRIPLETT, DOUGLAS A ^a   HARRIS, E NIGEL ^b  

^a BALL MEMORIAL HOSPITAL   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Anticardiolipin antibodies; fetal death; lupus anticoagulant; recurrent abortion

Indexed keywords

ACETYLSALICYLIC ACID; CARDIOLIPIN ANTIBODY; HEPARIN; IMMUNOGLOBULIN; PHOSPHOLIPID ANTIBODY; PREDNISONE;

CONFERENCE PAPER; ENZYME LINKED IMMUNOSORBENT ASSAY; FETUS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PLASMAPHERESIS; PREGNANCY; PREGNANCY COMPLICATION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RECURRENT ABORTION;

ABORTION, HABITUAL; ANIMAL; AUTOANTIBODIES; BLOOD COAGULATION FACTORS; CARDIOLIPINS; FEMALE; FETAL DEATH; HUMAN; INFERTILITY; LUPUS COAGULATION INHIBITOR; PHOSPHOLIPIDS; PREGNANCY; PREGNANCY COMPLICATIONS; REPRODUCTION;

EID: 0024957671     PISSN: 10467408     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/j.1600-0897.1989.tb01016.x     Document Type: Article

References (130)

1. Lupus anticoagulants: Misnomer, paradox, riddle, epiphenomenon
2. Antiphospholipid antibodies
3. Antiophospholipid antibodies and recurrent pregnancy loss
4. Biological false positive reactions and systemic disease
5. Biologically false positive serologic tests for syphilis: Type, incidence, and cause
6. Serologic test for syphilis: Guide to interpretation in various stages of disease
7. The natural history of systemic lupus erythematosus: An approach to its study through chronic biologic false positive reactions
8. Systemic lupus erythematosus preceded by false positive tests for syphilis: Presentation of five cases
9. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus
10. Acquired inhibitors of blood coagulation
11. Anticardiolipin antibodies: Detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus
12. Relationship between lupus anticoagulants and antibodies to phospholipids
13. Syndome hemorrhagique acquis du a un anticoagulant
14. Hypergamma‐globulinaemia, circulating anticoagulant, and biologic false positive wassermann reaction: A study of 2 cases
15. Intrauterine death and circulating anticoagulant, “antithromboplastin”
16. Avortements a repetion, thromboses, et anticoagulant circulant anti‐thromboplastine
17. Fetal loss in systemic lupus erythematosus: Association with anticardiolipin antibodies
18. Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus
19. Anticardiolipin antibodies in pregnant patients with systemic lupus erythematosus
20. Anticardiolipin antibody
21. Antibody to cardiolipin lupus anticoagulant and fetal death
22. Thrombosis, recurrent fetal losa and thrombocytopenia
23. Successful pregnancies in the antiphospholipid syndrome without prednisone
24. Lupus anticoagulant in women with multiple spontaneous miscarriage
25. Lupus anticoagulant in pregnancy
26. Successful pregnancy in systemic lupus erythematosus with an untreated lupus anticoagulant
27. Role of lupus anticoagulant and autoimmunity in recurrent pregnancy loss
28. Antibodies to phospholipids and nuclear antigens in patients with repeated abortions
29. Spontaneous recurrent fetal wastage and autoimmune abnormalities: A study of fourteen cases
30. The prevalence of antiphospholipid antibodies by ELISA technique, in patients with the lupus anticoagulant
31. Lupus anticoagulants and thrombosis
32. Chorea gravidarum associated with circulating lupus anticoagulant: Successful outcome of pregnancy with prednisone and aspirin therapy. Case report
33. Obstetric complications associated with the lupus anticoagulant
34. A “primary” antiphospholipid syndrome?
35. The association of antiphospholipid antibodies with severe preeclampsia
36. Anti‐cardiolipin antibodies and pre‐eclampsia
37. A new postpartum syndrome associated with antiphospholipid antibodies
38. Acquired circulating anticoagulants in systemic collagen disease
39. Antibody to cardiolipin and to RO/LA (SSA/SSB) antigens in maternal‐cord serum pairs
40. Maternal lupus anticoagulant and fatal neonatal thrombosis
41. Neonatal aortic thrombosis associated with the lupus anticoagulant
42. A mouse model for the reproductive autoimmune failure syndrome (RAFS): 1. Immunization with phospholipid antigens
43. A mouse model for the reproductive autoimmune failure syndrome (RAFS): 2. Effect on fertility
44. Lupus anticoagulants
45. Measurement of anticardiolipin antibodies by an enzyme linked immunosorbent assay (ELISA): Standardization and quantitation of results
46. Antiphospholipid antibodies: A review
47. Report of the working party on acquired inhibitors of coagulation: Studies of the ‘lupus’ anticoagulant
48. The varied sensitivity of partial thromboplastin and prothrombin reagents in the demonstration of lupus‐like anticoagulant
49. The diagnosis of lupus anticoagulants by the activated partial thromboplastin time—the central role of phosphatidyl serine
50. The sensitivity of different coagulation reagents to the presence of lupus anticoagulants
51. Hybridoma lupus anticoagulants distinguish between bilayer and nonbilayer phase lipid systems in autoimmunity: Experimental and clinical aspects
52. Lupus anticoagulant: A clinical and laboratory study of 100 cases
53. The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants
54. A sensitive test demonstrating lupus anticoagulant and its behavioral patterns
55. Lupus anticoagulant: An analysis of the clinical and laboratory features of 219 cases
56. Comparison of two simple tests for the lupus anticoagulants
57. Differences in kaolin‐clotting times and platelet counts resulting from variations in specimen processing
58. In vitro detection of mild inhibitors to factor VIII in hemophilia
59. Use of the agarose gel method to identify and quantitate factor VIII:C
60. A method for detecting factor VIII clotting activity associated with factor VIII related antigen in agarose gels
61. A clinical study of the lupus anticoagulant
62. The dilute phospholipid APTT: Evaluation of specificity for antibodies against cardiolipin and phosphatidylserine
63. Laboratory diagnosis of lupus inhibitors: A comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure
64. Lupus anticoagulants: Improved diagnosis with a kaolin clotting time using rabbit brain phospholipid in standard and high concentrations
65. Detection of antiphospholipid antibodies by ELISA method with bovine thromboplastin as antigen
66. Evaluation of the anticardiolipin antibody test: Report of an international workshop held 4 April 1986
67. Standardizing the anticardiolipin antibody test
68. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromembolic accidents, recurrent fetal loss, and a lupus anticoagulant
69. The lupus inhibitor in thromboembolic disease and intrauterine death in the absence of systemic lupus
70. Thromboembolism in patients with the “lupus” type circulating anticoagulant
71. Lupus anticoagulant in pregnancy
72. Uteroplacental vascular pathology
73. Review article: Acute atherosis. A histopathological hallmark of immune aggression?
74. Placental lesions in maternal autoimmune diseases
75. Decidual arteriopathy in hypertension and diabetes in pregnancy: Immunofluoresant studies
76. IgM antitrophoblast antibodies in a patient with a pregnancy associated lupuslike disorder, vasculitis and recurrent intrauterine fetal demise
77. Natural anticoagulant mechanisms
78. Thrombosis and immune disorders
79. The lupus anticoagulant and its role in thrombosis
80. Lupus anticoagulant and inhibition of prostacyclin formation in patients with repeated abortion, intrauterine growth retardation and intrauterine death
81. Arterial thrombosis, intrauterine death and “lupus” anticoagulant: Detection of immunoglobulin interfering with prostacylin formation
82. Lupus anticoagulant and vascular prostacyclin production
83. The effect of anticardiolipin positive sera from SLE patients on platelet and endothelial prostancid synthesis
84. The lupus anticoagulant does not inhibit the release of prostacyclin from human endothelial cells
85. Evaluation of lupus anticoagulants: Antiophspholipid antibodies, endothelial associated immunoglobulin, endothelial prostacyclin secretion, and antigenic protein S levels
86. Prekallikrein inhibition associated with the lupus anticoagulant: A mechanism of thrombosis
87. Kallikrein inhibition and C‐1 esterase inhibitor levels in patients with lupus inhibitor
88. Immune mediated mechanism for thrombosis: Antiphospholipid antibody binding to platelet membrane
89. Low functional and high antigenic antithrombin III level in a patient with the lupus anticoagulant and recurrent thrombosis
90. Antibody and immune complexes induce tissue factor production by endothelial cells
91. Human thrombomodulin is inhibited by IgG from two patients with nonspecific anticoagulants
92. An IgM lupus anticoagulant that neutralizes the enhancing effect of phospholipid on purified endothelial thrombomodulin activity—a mechanism for thrombosis
93. Lupus‐like anticoagulants modulation of the protein C pathway and thrombosis
94. Lupus anticoagulant risk factor of thrombosis by inhibition of protein C activation
95. Anticardiolipin antibodies: Smoking gun or smoke screen?
96. Predicative value of anticardiolipin antibodies in antenatal screening of routine pregnancy
97. Lupus anticoagulant and pregnancy management
98. Lupus anticoagulant in pregnancy
99. Antiphospholipid antibodies and pregnancy
100. Lupus anticoagulant and recurrent pregnancy failure
101. Lupus anticoagulant and pregnancy
102. Fetal survival after prednisone suppression of maternal lupus anticoagulant
103. Monitoring lupus anticoagulant—positive pregnancies with umbilical artery flow velocity waveforms
104. A comparison of fetal heart rate monitoring and umbilical artery waveforms recognition of fetal compromise
105. Umbilical artery flow velocity waveforms and placental resistence: The effects of embolization of the umbilical circulation
106. Low‐dose aspirin inhibits thromboxane, but not prostacyclin production by human placental arteries
107. Anticardiolipin antibodies during pregnancy
108. Discordant effects of prednisone on anticardiolipin antibodies and the lupus anticoagulant
109. Antepartum fetal heart rate testing. VII. The significance of fetal bradycardia
110. Prednisone and maternal lupus anticoagulant
111. Recurrent abortion with lupus anticoagulant and pre‐eclampsia: A common final pathway for two different disease? Case report
112. Successful pregnancy following suppression of anticardiolipin antibody and lupus anticoagulant with azathioprine in systemic lupus erythematosus
113. Fetal heart block, anti SSA and SSB, antibodies associated with intra‐uterine growth retardation, fetal death, and lupus anticoagulant
114. A comparison of pregnancy outcome after two treatments for antibodies to cardiolipin
115. A controlled clinical trial on the efficacy of medicamentous treatment of pregnant patients with antiphospholipid antibodies—a preliminary report
116. Anticardiolipin antibodies and pregnancy
117. Heparin therapy for prevention of fetal wastage in women with anticardiolipin antibodies and lupus anticoagulant
118. Maternal and fetal sequelae of anticoagulation during pregnancy
119. Low molecular weight heparin (PK 10164) does not cross the placenta during the second trimester of pregnancy study by direct fetal blood sampling under ultrasound
120. Lack of efficacy of plasma‐exchange in removing antiphospholipid antibodies
121. Successful removal of antiphospholipid antibody during pregnancy using plasma exchange and low‐dose prednisolone
122. Successful removal of antiphospholipid antibodies using repeated plasma exchanges and prednisone
123. Prevention of recurrent idiopathic fetal growth retardation by low dose aspirin and dipyridamole
124. Prophylactic low dose aspirin and dipyridamole in pregnancy
125. Intravenous IgG therapy for anticardiolipin syndrome: A case report
126. Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy loss caused by antiphospholipid antibodies and Rh immunization
127. Lupus anticoagulant and recurrent fetal loss: Successful treatment with gammaglobulin
128. Repeated fetal losses and the lupus anticoagulant
129. Intravenous gamma‐globulin, antiphospholipid antibodies and pregnancy
130. KAPS group plans major prospective studies on antiphospholipid antibodies, fetal loss, and thrombosis